HIP1 expression predicts outcome in breast cancer patients treated with neoadjuvant chemotherapy

Mireia Margeli, Vanesa Quiroga, Gustavo Tapia, Eva Castella, Montserrat Sola, Mireia Morgades, Rafael Rosell, Agustí Barnadas, Beatriz Cirauqui

Research output: Contribution to journalArticleResearchpeer-review

Abstract

© 2017 Introduction Huntingtin-interacting protein 1 (HIP1) binds to inositol and clathrin, which is related to neurodegeneration. Signaling of growth factors receptors through clathrin is one mechanism by which cells regulate intracellular signaling. High levels of HIP1 protein have been observed in breast, colon, kidney, lung, ovarian and prostate cancer and melanoma. Methods Tumor biopsies were obtained from 83 breast cancer patients (p) treated with four cycles of fluorouracil, epirubicin and cyclophosphamide neoadjuvant chemotherapy. Estrogen receptor, progesterone receptor, HER2, cytokeratin 5/6, vimentin and HIP1 were examined by tissue microarray. HER2 was also assessed by chromogenic in situ hybridization and the prognostic and predictive value of HIP1 expression was evaluated. Results HIP1 was evaluated by immunohistochemistry (IHC) in 83 p, considered negative if the result was 0, and positive if it was 1, 2 or 3. The result was 0 in 11 p (13.3%), 1 in 40 p (48.2%), 2 in 25 p (30.1%), and 3 in 7 p (8.4%). Negative HP1 was correlated with poorly differentiated tumors (p=0.021) and triple negative tumors (p=0.038). Negative HIP1 was not correlated with response but HIP1 negative was correlated with shorter time to progression (TTP) (p=0.003) and overall survival (OS) (p=0.009). Conclusions HIP1 could be a prognostic and predictive factor in breast cancer.
Original languageEnglish
Pages (from-to)21-26
JournalCancer Treatment and Research Communications
Volume11
DOIs
Publication statusPublished - 1 Jan 2017

Keywords

  • Clathrin-mediated endocytosis
  • Huntingtin-interacting protein 1
  • Overall survival
  • Time to progression

Fingerprint Dive into the research topics of 'HIP1 expression predicts outcome in breast cancer patients treated with neoadjuvant chemotherapy'. Together they form a unique fingerprint.

Cite this